Hansoh Pharmaceutical Group Company 주식 주식분석 | 주식가격 | 뉴스 | 3692.HK | KYG549581067 | A2PLRC

날짜	Hansoh Pharmaceutical Group Company 매출	Hansoh Pharmaceutical Group Company EBIT	Hansoh Pharmaceutical Group Company 이익
2029e	17.61 조. undefined	0 undefined	0 undefined
2028e	16.25 조. undefined	5.61 조. undefined	0 undefined
2027e	14.91 조. undefined	5.25 조. undefined	0 undefined
2026e	14.13 조. undefined	4.39 조. undefined	4.28 조. undefined
2025e	12.65 조. undefined	3.89 조. undefined	3.77 조. undefined
2024e	12.1 조. undefined	3.87 조. undefined	3.77 조. undefined
2023	10.1 조. undefined	2.65 조. undefined	3.28 조. undefined
2022	9.38 조. undefined	2.57 조. undefined	2.58 조. undefined
2021	9.94 조. undefined	2.96 조. undefined	2.71 조. undefined
2020	8.69 조. undefined	2.78 조. undefined	2.57 조. undefined
2019	8.68 조. undefined	2.8 조. undefined	2.56 조. undefined
2018	7.72 조. undefined	2.26 조. undefined	1.9 조. undefined
2017	6.19 조. undefined	1.91 조. undefined	1.6 조. undefined
2016	5.43 조. undefined	1.79 조. undefined	1.48 조. undefined

	매출	EBIT	이익
2016	5.43 조. CNY	1.79 조. CNY	1.48 조. CNY
2017	6.19 조. CNY	1.91 조. CNY	1.6 조. CNY
2018	7.72 조. CNY	2.26 조. CNY	1.9 조. CNY
2019	8.68 조. CNY	2.8 조. CNY	2.56 조. CNY
2020	8.69 조. CNY	2.78 조. CNY	2.57 조. CNY
2021	9.94 조. CNY	2.96 조. CNY	2.71 조. CNY
2022	9.38 조. CNY	2.57 조. CNY	2.58 조. CNY
2023	10.1 조. CNY	2.65 조. CNY	3.28 조. CNY
2024e	12.1 조. CNY	3.87 조. CNY	3.77 조. CNY
2025e	12.65 조. CNY	3.89 조. CNY	3.77 조. CNY
2026e	14.13 조. CNY	4.39 조. CNY	4.28 조. CNY
2027e	14.91 조. CNY	5.25 조. CNY	0 CNY
2028e	16.25 조. CNY	5.61 조. CNY	0 CNY
2029e	17.61 조. CNY	0 CNY	0 CNY

2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
5.43	6.19	7.72	8.68	8.69	9.94	9.38	10.1	12.1	12.65	14.13	14.91	16.25	17.61
-	13.86	24.85	12.43	0.09	14.33	-5.57	7.68	19.80	4.48	11.78	5.51	8.98	8.38
92.69	92.64	92.19	91.60	90.75	91.23	90.73	89.79	-	-	-	-	-	-
5.04	5.73	7.12	7.95	7.89	9.06	8.51	9.07	0	0	0	0	0	0
1.79	1.91	2.26	2.8	2.78	2.96	2.57	2.65	3.87	3.89	4.39	5.25	5.61	0
32.90	30.95	29.20	32.22	32.03	29.78	27.34	26.19	31.96	30.77	31.03	35.17	34.49	-
1.48	1.6	1.9	2.56	2.57	2.71	2.58	3.28	3.77	3.77	4.28	0	0	0
-	8.06	19.31	34.31	0.47	5.61	-4.76	26.87	14.89	0.24	13.51	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-
5.16	5.16	5.16	5.48	5.88	6	5.93	6.02	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022
1.8	1.93	2.31	3	3.1	3.3	2.95
119	135	156	201	233	278	344
0	0	0	0	0	0	0
-669	-644	-350	291	-806	-747	-629
-6	-21	-43	-163	-134	-253	77
3	0	0	0	0	0	0
311	231	306	541	590	319	324
1.25	1.4	2.07	3.33	2.39	2.58	2.74
-238	-256	-381	-592	-1,427	-460	-272
829	-614	-1,388	-7,075	-2,874	-2,259	-5,935
1.07	-0.36	-1.01	-6.48	-1.45	-1.8	-5.66
0	0	0	0	0	0	0
-0.05	0	0	-0.04	-0.01	3.84	-0.04
1.3	0	0	9.53	3.17	-0.04	-0.06
-2.05	-0.73	0	7.99	-1.04	3.42	-0.82
-3,301.00	-730.00	-	-	-	-	-
0	0	0	-1,500	-4,200	-380	-712
0.05	0.06	0.7	4.38	-2.28	3.66	-4.05
1,007.58	1,145.91	1,690.85	2,737.21	962.83	2,117.03	2,468.38
0	0	0	0	0	0	0

Hansoh Pharmaceutical Group Company 브루토마진	Hansoh Pharmaceutical Group Company 이익 마진	Hansoh Pharmaceutical Group Company EBIT-마진	Hansoh Pharmaceutical Group Company 이익 마진
2029e	89.78 %	0 %	0 %
2028e	89.78 %	34.49 %	0 %
2027e	89.78 %	35.17 %	0 %
2026e	89.78 %	31.03 %	30.31 %
2025e	89.78 %	30.77 %	29.85 %
2024e	89.78 %	31.96 %	31.11 %
2023	89.78 %	26.19 %	32.44 %
2022	90.73 %	27.34 %	27.54 %
2021	91.24 %	29.79 %	27.31 %
2020	90.76 %	32.03 %	29.56 %
2019	91.6 %	32.22 %	29.45 %
2018	92.19 %	29.21 %	24.64 %
2017	92.64 %	30.95 %	25.79 %
2016	92.69 %	32.89 %	27.17 %

	브루토마진	EBIT-마진	이익 마진
2016	92.69 %	32.89 %	27.17 %
2017	92.64 %	30.95 %	25.79 %
2018	92.19 %	29.21 %	24.64 %
2019	91.6 %	32.22 %	29.45 %
2020	90.76 %	32.03 %	29.56 %
2021	91.24 %	29.79 %	27.31 %
2022	90.73 %	27.34 %	27.54 %
2023	89.78 %	26.19 %	32.44 %
2024e	89.78 %	31.96 %	31.11 %
2025e	89.78 %	30.77 %	29.85 %
2026e	89.78 %	31.03 %	30.31 %
2027e	89.78 %	35.17 %	0 %
2028e	89.78 %	34.49 %	0 %
2029e	89.78 %	0 %	0 %

날짜	Hansoh Pharmaceutical Group Company 주당 매출	Hansoh Pharmaceutical Group Company EBIT 당 주식	Hansoh Pharmaceutical Group Company 주당 이익
2029e	2.97 undefined	0 undefined	0 undefined
2028e	2.74 undefined	0 undefined	0 undefined
2027e	2.52 undefined	0 undefined	0 undefined
2026e	2.39 undefined	0 undefined	0.72 undefined
2025e	2.13 undefined	0 undefined	0.64 undefined
2024e	2.04 undefined	0 undefined	0.64 undefined
2023	1.68 undefined	0.44 undefined	0.54 undefined
2022	1.58 undefined	0.43 undefined	0.44 undefined
2021	1.66 undefined	0.49 undefined	0.45 undefined
2020	1.48 undefined	0.47 undefined	0.44 undefined
2019	1.59 undefined	0.51 undefined	0.47 undefined
2018	1.5 undefined	0.44 undefined	0.37 undefined
2017	1.2 undefined	0.37 undefined	0.31 undefined
2016	1.05 undefined	0.35 undefined	0.29 undefined

	주당 매출	EBIT 당 주식	주당 이익
2016	1.05 CNY	0.35 CNY	0.29 CNY
2017	1.2 CNY	0.37 CNY	0.31 CNY
2018	1.5 CNY	0.44 CNY	0.37 CNY
2019	1.59 CNY	0.51 CNY	0.47 CNY
2020	1.48 CNY	0.47 CNY	0.44 CNY
2021	1.66 CNY	0.49 CNY	0.45 CNY
2022	1.58 CNY	0.43 CNY	0.44 CNY
2023	1.68 CNY	0.44 CNY	0.54 CNY
2024e	2.04 CNY	0 CNY	0.64 CNY
2025e	2.13 CNY	0 CNY	0.64 CNY
2026e	2.39 CNY	0 CNY	0.72 CNY
2027e	2.52 CNY	0 CNY	0 CNY
2028e	2.74 CNY	0 CNY	0 CNY
2029e	2.97 CNY	0 CNY	0 CNY

	주식 수량
2016	5.16 조. Aktien
2017	5.16 조. Aktien
2018	5.16 조. Aktien
2019	5.48 조. Aktien
2020	5.88 조. Aktien
2021	6 조. Aktien
2022	5.93 조. Aktien
2023	6.02 조. Aktien
2024e	6.02 조. Aktien
2025e	6.02 조. Aktien
2026e	6.02 조. Aktien
2027e	6.02 조. Aktien
2028e	6.02 조. Aktien
2029e	6.02 조. Aktien

날짜	Hansoh Pharmaceutical Group Company 배당금
2029e	0.2 undefined
2028e	0.2 undefined
2027e	0.2 undefined
2026e	0.21 undefined
2025e	0.2 undefined
2024e	0.21 undefined
2023	0.19 undefined
2022	0.23 undefined
2021	0.08 undefined

	배당금	배당금 (추정)
2016	0 CNY	0 CNY
2017	0 CNY	0 CNY
2018	0 CNY	0 CNY
2019	0 CNY	0 CNY
2020	0 CNY	0 CNY
2021	0.08 CNY	0 CNY
2022	0.23 CNY	0 CNY
2023	0.19 CNY	0 CNY
2024e	0 CNY	0.21 CNY
2025e	0 CNY	0.2 CNY
2026e	0 CNY	0.21 CNY
2027e	0 CNY	0.2 CNY
2028e	0 CNY	0.2 CNY
2029e	0 CNY	0.2 CNY

날짜	Hansoh Pharmaceutical Group Company 배당률
2029e	37.8 %
2028e	38.6 %
2027e	37.72 %
2026e	37.07 %
2025e	41 %
2024e	35.1 %
2023	35.1 %
2022	52.78 %
2021	17.43 %
2020	35.1 %
2019	35.1 %
2018	35.1 %
2017	35.1 %
2016	35.1 %

	배당률
2016	35.1 %
2017	35.1 %
2018	35.1 %
2019	35.1 %
2020	35.1 %
2021	17.43 %
2022	52.78 %
2023	35.1 %
2024e	35.1 %
2025e	41 %
2026e	37.07 %
2027e	37.72 %
2028e	38.6 %
2029e	37.8 %

%-지분	이름	주식	변경
65.81 %	Zhong (Huijuan)	3,900,000,000	0
16.03 %	Cen (Junda)	950,000,000	0
1.92 %	Fidelity Management & Research Company LLC	113,965,695	11,777,867
0.53 %	The Vanguard Group, Inc.	31,343,444	-360,000
0.50 %	FIL Investment Management (Hong Kong) Limited	29,735,359	-1,757,555
0.46 %	UBS Asset Management (Hong Kong) Limited	27,523,481	-22,000
0.41 %	BlackRock Institutional Trust Company, N.A.	24,052,609	-250,000
0.35 %	Federated Hermes International	20,700,249	243,568
0.34 %	FIL Investment Management (Singapore) Ltd.	20,295,197	-2,810,023
0.32 %	Bosera Asset Management Co., Ltd.	19,032,000	4,672,000
0.30 %	Hang Seng Investment Management Ltd.	17,848,002	-239,454
0.28 %	Fidelity International	16,361,328	-867,816
0.26 %	BlackRock Advisors (UK) Limited	15,344,000	446,000
0.24 %	GF Fund Management Co., Ltd.	14,358,000	8,792,000
0.23 %	State Street Global Advisors Asia Ltd.	13,365,578	52,380
0.22 %	APG Asset Management N.V.	13,197,027	12,046,080
0.19 %	ZhongGeng Fund Management Co., Ltd.	11,328,000	6,758,000
0.18 %	Norges Bank Investment Management (NBIM)	10,786,186	-3,033,404
0.15 %	China Asset Management Co., Ltd.	8,700,000	3,414,156
0.11 %	E Fund Management Co. Ltd.	6,348,000	4,970,000
0.09 %	Geode Capital Management, L.L.C.	5,530,000	298,000
0.08 %	HuaAn Fund Management Co., Ltd.	4,834,000	4,812,000
0.08 %	Dimensional Fund Advisors, L.P.	4,750,000	0
0.08 %	Pictet Asset Management Ltd.	4,480,000	-86,000
0.06 %	Amundi Asset Management, SAS	3,766,000	160,000
0.06 %	Northern Trust Global Investments Limited	3,419,084	0
0.06 %	UBS Asset Management (UK) Ltd.	3,324,970	-84,000
0.05 %	Royal London Asset Management Ltd.	3,208,000	0
0.05 %	JPMorgan Asset Management (Asia Pacific) Limited	3,072,000	354,000
0.05 %	Royal London Asset Management (CIS) Limited_NLE	2,782,000	0
0.04 %	CPP Investment Board	2,593,000	2,593,000
0.04 %	INVESCO Asset Management Limited	2,564,000	-4,000
0.04 %	Essence Fund Management Co., Ltd.	2,454,000	2,444,000
0.04 %	Aviva Investors Global Services Limited	2,089,778	-212,884
0.03 %	Credit Suisse Funds AG	2,064,000	54,000
0.03 %	China Universal Asset Management Co., Ltd.	1,868,000	678,000
0.03 %	Nuveen LLC	1,803,582	1,162
0.03 %	Amundi Japan Ltd.	1,750,000	-24,000
0.03 %	BlackRock (Singapore) Limited	1,721,321	427,474
0.03 %	China Asset Management (Hong Kong) Limited	1,578,505	-83,236
0.03 %	State Street Global Advisors (US)	1,554,087	-50,000
0.03 %	DWS Investment GmbH	1,540,144	37,391
0.03 %	CSOP Asset Management Limited	1,488,729	31,703
0.03 %	Harvest Fund Management Co., Ltd.	1,486,000	252,000
0.02 %	State Street Global Advisors (UK) Ltd.	1,437,980	2
0.02 %	DWS Investments UK Limited	1,437,610	23,085
0.02 %	Charles Schwab Investment Management, Inc.	1,267,724	0
0.02 %	Penghua Fund Management Co., Ltd.	1,262,000	200,000
0.02 %	Mirae Asset Global Investments (Hong Kong) Limited	1,122,286	241,242
0.02 %	HSBC Global Asset Management (UK) Limited	1,081,556	-57,563
0.02 %	Storebrand Kapitalforvaltning AS	1,054,602	26,000
0.02 %	BlackRock Investment Management (UK) Ltd.	1,052,000	-74,000
0.02 %	Handelsbanken Kapitalförvaltning AB	1,008,000	72,000
0.02 %	Fullgoal Fund Management Co., Ltd.	972,000	742,000
0.02 %	Lyu (Aifeng)	955,500	90,000
0.02 %	KLP Fondsforvaltning AS	934,000	0
0.02 %	GAM International Management Ltd.	900,000	0
0.01 %	UBS Asset Management (Switzerland)	888,000	0
0.01 %	Irish Life Investment Managers Ltd.	860,900	-3,100
0.01 %	PGGM Vermogensbeheer B.V.	859,328	3,043
0.01 %	Bank of China Investment Management Co., Ltd.	856,000	620,000
0.01 %	Goldman Sachs Advisors B.V._NLE	822,000	56,000
0.01 %	Zürcher Kantonalbank (Asset Management)	780,480	220,000
0.01 %	Mercer Global Investments Management Ltd	777,809	0
0.01 %	China Southern Asset Management Co. Ltd.	760,000	228,000
0.01 %	American Century Investment Management, Inc.	750,000	128,000
0.01 %	Mellon Investments Corporation	738,100	122,000
0.01 %	Dimensional Fund Advisors, Ltd.	704,000	0
0.01 %	Lazard Asset Management, L.L.C.	696,000	0
0.01 %	Baoying Fund Management Co., Ltd.	622,719	622,719
0.01 %	BOCI-Prudential Asset Management Ltd.	586,744	0
0.01 %	Robeco Institutional Asset Management B.V.	544,000	390,000
0.01 %	Legal & General Investment Management Ltd.	540,000	-64,000
0.01 %	Northern Trust Investments, Inc.	530,000	-8,000
0.01 %	Tianhong Asset Management Co., Ltd.	526,000	234,000
0.01 %	Yinhua Fund Management Co., Ltd.	482,000	302,000
0.01 %	British Columbia Investment Management Corp.	481,158	-15,539
0.01 %	Cardano Asset Management NV	475,137	55
0.01 %	GAM (Luxembourg) S.A.	450,000	-100,000
0.01 %	California State Teachers Retirement System	442,000	-90,000
0.01 %	Swedbank Robur Fonder AB	424,000	-22,000
0.01 %	BMO Asset Management Inc.	419,440	0
0.01 %	Sun (Yuan)	408,100	408,100
0.01 %	Maxwealth Fund Management Co., Ltd.	400,000	400,000
0.01 %	Bellevue Asset Management AG	400,000	100,000
0.01 %	Eurizon Capital S.A.	386,393	6,254
0.01 %	Hony Horizon Fund Management Co., Ltd.	386,000	386,000
0.01 %	Mirae Asset Global Investments (USA) LLC	347,943	6,000
0.01 %	Hwabao WP Fund Management Co., Ltd.	340,000	154,000
0.01 %	Morgan Stanley Investment Management (China) Company Limited.	338,000	338,000
0.01 %	Krane Funds Advisors, LLC	336,000	0
0.01 %	UBS Asset Management Switzerland AG	334,000	0
0.01 %	Nykredit Bank AS	326,000	86,000
0.01 %	Vestcor Inc	314,081	-158,824
0.01 %	Guliver Anlageberatung GmbH	306,000	64,000
0.00 %	Vanguard Investments Australia Ltd.	295,611	151
0.00 %	OP Varainhoito Oy	286,000	0
0.00 %	Huatai-PineBridge Fund Management Co., Ltd.	268,630	20,000
0.00 %	Degroof Petercam Asset Management	262,269	0
0.00 %	Oberweis Asset Management, Inc.	250,000	250,000

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

Hansoh Pharmaceutical Group Co Ltd represents values of innovation, quality, and patient-centricity. With a strong corporate philosophy, the company focuses on developing and delivering high-quality pharmaceutical products that improve and save lives. Hansoh Pharmaceutical Group Co Ltd's commitment to innovation drives the development of new and effective therapies to address unmet medical needs. The company's patient-centric approach ensures that their products are developed and manufactured with the highest quality standards, aiming to provide optimal healthcare solutions for patients worldwide. Hansoh Pharmaceutical Group Co Ltd's dedication to excellence makes them a trusted and reliable player in the pharmaceutical industry.

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

Hansoh Pharmaceutical Group Co Ltd is primarily present in China.

What significant milestones has the company Hansoh Pharmaceutical Group Company achieved?

Hansoh Pharmaceutical Group Co Ltd has achieved several significant milestones. In recent years, the company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, marking a major milestone in its financial development. Additionally, Hansoh Pharmaceutical Group has made significant advancements in its research and development efforts, resulting in the successful launch of innovative and high-quality pharmaceutical products. The company has also expanded its global footprint by establishing strategic collaborations and partnerships with international pharmaceutical companies. Overall, Hansoh Pharmaceutical Group Co Ltd continues to make notable strides in the pharmaceutical industry, solidifying its position as a leading player in the market.

What is the history and background of the company Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Co Ltd is a leading pharmaceutical company with a rich history and background. Founded in 1995, the company has rapidly grown to become one of the largest and most respected pharmaceutical companies in China. Hansoh Pharmaceutical focuses on the research, development, manufacturing, and commercialization of innovative drugs in various therapeutic areas like oncology, diabetes, and cardiovascular diseases. With a strong emphasis on innovation and quality, Hansoh Pharmaceutical has successfully introduced numerous blockbuster drugs, gaining recognition both domestically and internationally. The company's commitment to excellence and patient care has established it as a trusted name in the pharmaceutical industry.

Who are the main competitors of Hansoh Pharmaceutical Group Company in the market?

The main competitors of Hansoh Pharmaceutical Group Co Ltd in the market include well-known pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co Ltd, Jiangsu Hengrui Medicine Co Ltd, and Sino Biopharmaceutical Ltd. These companies compete with Hansoh Pharmaceutical Group Co Ltd in terms of research and development, product portfolio, market presence, and overall performance in the pharmaceutical industry.

In which industries is Hansoh Pharmaceutical Group Company primarily active?

Hansoh Pharmaceutical Group Co Ltd primarily operates in the pharmaceutical industry.

What is the business model of Hansoh Pharmaceutical Group Company?

The business model of Hansoh Pharmaceutical Group Co Ltd is focused on research, development, manufacturing, and commercialization of innovative pharmaceutical products. As one of the leading pharmaceutical companies in China, Hansoh Pharmaceutical Group Co Ltd aims to provide high-quality and affordable medications to improve the well-being of individuals. The company collaborates with healthcare professionals and institutions to meet the evolving healthcare needs of patients. Hansoh Pharmaceutical Group Co Ltd's business model emphasizes continuous innovation, leveraging cutting-edge technology, and maintaining strong partnerships across the industry. Through its diversified portfolio and commitment to excellence, the company strives to contribute to the advancement of healthcare in China and globally.

Hansoh Pharmaceutical Group Company 2024의 P/E 비율은 얼마입니까?

Hansoh Pharmaceutical Group Company의 P/E 비율은 23.63입니다.

Hansoh Pharmaceutical Group Company 2024의 KUV는 얼마입니까?

Hansoh Pharmaceutical Group Company의 P/S 비율은 7.35입니다.

Hansoh Pharmaceutical Group Company의 AlleAktien 품질 점수는 얼마인가요?

Hansoh Pharmaceutical Group Company에 대한 AlleAktien 품질 점수는 3/10입니다.

Hansoh Pharmaceutical Group Company 2024의 매출은 얼마인가요?

예상되는 Hansoh Pharmaceutical Group Company 매출은 12.1 조. CNY입니다.

Hansoh Pharmaceutical Group Company 2024의 이익은 얼마인가요?

예상되는 Hansoh Pharmaceutical Group Company 이익은 3.77 조. CNY입니다.

Hansoh Pharmaceutical Group Company은 무엇을 하나요?

Hansoh Pharmaceutical Group Co Ltd is a leading Chinese pharmaceutical company specializing in research, development, production, and distribution of innovative and generic drugs. The company originated in Jiangsu province, China and operates globally today. The business model of Hansoh consists of various divisions focusing on drug development, manufacturing, distribution, and marketing. The company has a strong presence in the Asian market and is expanding its business worldwide. The divisions of Hansoh include research and development of new drugs, generics, over-the-counter products, and biological drugs. The company is renowned for its capabilities in active ingredient research, development, and manufacturing. Hansoh's products cover a wide range of therapeutic areas including oncology, cardiology, neurology, and infectious diseases. In the research and development field, Hansoh drives growth through investments in cutting-edge technologies like new drug research in collaboration with universities and research institutes, artificial intelligence and big data, as well as close cooperation with other companies. The generics division is a crucial part of Hansoh's business model. The company offers a wide range of generics, providing a cost-effective yet effective alternative to expensive brand-name products. The company works towards lowering production costs in the long term and facilitating access to medication for patients worldwide. Additionally, the company operates in the over-the-counter (OTC) sector, offering products such as vitamins, pain relievers, and non-prescription medications. Hansoh also focuses heavily on biological drugs, particularly in the field of antibody therapy. Here, the company works on developing new drugs for the treatment of cancer and other serious illnesses. To make Hansoh Pharma's business successful, the company has established a strong presence in key markets around the world. Collaboration with other pharmaceutical companies to jointly market and distribute their products is a crucial aspect. For example, Germany and the USA are important markets for the company. Overall, the business model of Hansoh Pharmaceutical Group Co Ltd is focused on the long-term sustainability and growth of their business. Through a combination of innovative development and production processes, a broad portfolio of drugs, and a strong presence in key markets worldwide, the company remains on a growth trajectory and will establish itself as a significant player in the global pharmaceutical industry in the future.

Hansoh Pharmaceutical Group Company 배당금은 얼마입니까?

Hansoh Pharmaceutical Group Company은(는) 연간 번의 배당을 통해 0.23 CNY의 배당금을 지급합니다.

Hansoh Pharmaceutical Group Company이 얼마나 자주 배당을 지급하나요?

Hansoh Pharmaceutical Group Company의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Hansoh Pharmaceutical Group Company ISIN이 무엇입니까?

Hansoh Pharmaceutical Group Company의 ISIN은 KYG549581067입니다.

Hansoh Pharmaceutical Group Company WKN은 무엇인가요?

Hansoh Pharmaceutical Group Company의 WKN은 A2PLRC입니다.

Hansoh Pharmaceutical Group Company 티커는 무엇인가요?

Hansoh Pharmaceutical Group Company의 티커는 3692.HK입니다.

Hansoh Pharmaceutical Group Company이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Hansoh Pharmaceutical Group Company은(는) 0.19 CNY 의 배당금을 지급했습니다. 이는 약 1.3 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Hansoh Pharmaceutical Group Company은(는) 0.2 CNY의 배당금을 지급할 것으로 예상됩니다.

Hansoh Pharmaceutical Group Company의 배당 수익률은 얼마입니까?

Hansoh Pharmaceutical Group Company의 현재 배당 수익률은 1.3 %입니다.

Hansoh Pharmaceutical Group Company의 배당금은 언제 지급되나요?

Hansoh Pharmaceutical Group Company은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Hansoh Pharmaceutical Group Company의 배당금은 얼마나 안전한가요?

Hansoh Pharmaceutical Group Company은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Hansoh Pharmaceutical Group Company의 배당금은 얼마입니까?

향후 12개월 동안 0.2 CNY의 배당금이 예상됩니다. 이는 배당수익률 1.37 %에 해당합니다.

Hansoh Pharmaceutical Group Company이(가) 속해 있는 섹터는 어디인가요?

Hansoh Pharmaceutical Group Company은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Hansoh Pharmaceutical Group Company kaufen, um die vorherige Dividende zu erhalten?

Hansoh Pharmaceutical Group Company의 마지막 배당금을 0.142 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Hansoh Pharmaceutical Group Company의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Hansoh Pharmaceutical Group Company의 2023년도 배당금은 얼마였습니까?

2023년에 Hansoh Pharmaceutical Group Company는 0.23 CNY를 배당금으로 지급했습니다.

Hansoh Pharmaceutical Group Company는 어떤 화폐로 배당금을 지급하나요?

Hansoh Pharmaceutical Group Company의 배당금은 CNY에 지급됩니다.

Scope 1 - 직접 방출	9,024.6
스코프 2 - 구매한 에너지로부터의 간접적인 배출	77,719.97
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	86,744.57
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	❌
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	✅
환경 친화적인 포장	✅
위험물질	✅
연료 소비량과 효율성	✅
물 사용량 및 효율성	✅

여성 직원 비율	35.769
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	✅
개인정보 보호 정책	—
작업 및 건강 보호	✅
카톨릭	✅

환경 보고	✅
이해관계자 참여	✅
콜백 정책	❌
카르텔법	❌

증권거래소	Hansoh Pharmaceutical Group Company 티커
프랑크푸르트	3KY.F
HKSE	3692.HK
뮌헨	3KY.MU

Hansoh Pharmaceutical Group Company 티커	Hansoh Pharmaceutical Group Company FIGI
3692:HK	BBG00P78Y7N1
3692EUR:XS	BBG00PG9MD40
3692EUR:XH	BBG00PG9MD77
3692EUR:XF	BBG00PG9MD95
3692EUR:XE	BBG00PG9MDC1
3692EUR:XJ	BBG00PG9MDD0
3692EUR:XL	BBG00PG9MDF8
3692EUR:XG	BBG00PG9MDG7
3692EUR:XO	BBG00PG9MDH6
3692EUR:XA	BBG00PG9MDM0
3692EUR:E1	BBG00PG9MDN9
3692EUR:XT	BBG00PG9MDP7
3692EUR:XW	BBG00PG9MDQ6
3692EUR:XU	BBG00PG9MDR5
3692EUR:XV	BBG00PG9MDS4
3692EUR:XM	BBG00PG9MDT3
3692EUR:XQ	BBG00PG9MDV0
3692EUR:XX	BBG00PG9MDW9
3692EUR:XZ	BBG00PG9MDX8
3692EUR:EU	BBG00PG9MDZ6
3KY:TH	BBG00PGKL8X5
3KY:GR	BBG00PGLT3M8
3KY:GF	BBG00PGLT3N7
3KY:GS	BBG00PGLT3R3
3KY:GM	BBG00PGLT3S2
3692HKD:EP	BBG00PH03PP9
3692HKD:EZ	BBG00PH03PR7
3692HKD:XS	BBG00PH03PS6
3692HKD:XH	BBG00PH03PW1
3692HKD:XF	BBG00PH03PY9
3692HKD:XE	BBG00PH03Q04
3692HKD:XJ	BBG00PH03Q13
3692HKD:XL	BBG00PH03Q22
3692HKD:XG	BBG00PH03Q31
3692HKD:XO	BBG00PH03Q40
3692HKD:XA	BBG00PH03Q86
3692HKD:E1	BBG00PH03Q95
3692HKD:XT	BBG00PH03QB2
3692HKD:XW	BBG00PH03QC1
3692HKD:XU	BBG00PH03QD0
3692HKD:XV	BBG00PH03QF8
3692HKD:XM	BBG00PH03QG7
3692HKD:XQ	BBG00PH03QH6
3692HKD:XX	BBG00PH03QJ4
3692HKD:XZ	BBG00PH03QK2
3692HKD:EU	BBG00PH03QN9
3692:H1	BBG00Q6WB3D2
3692:H2	BBG00Q6WBGD3
3KY:GZ	BBG00W9LMHM7
3692EUR:EP	BBG00W9LR9N9
3692EUR:EZ	BBG00W9LR9Q6
HNSPF:US	BBG00Z8393Z3
HNSPF:PQ	BBG00Z8394D5
HNSPF:UV	BBG00Z8394F3
3KY:LA	BBG018H9RRP7
3KY:LU	BBG018J3F9G1

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커3692.HK

ISINKYG549581067

WKNA2PLRC

Hansoh Pharmaceutical Group Company 주식 매출, EBIT, 이익 KYG549581067 · A2PLRC

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Hansoh Pharmaceutical Group Company 매출, 이익 및 EBIT 역사

Hansoh Pharmaceutical Group Company 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Hansoh Pharmaceutical Group Company 주식 마진 KYG549581067 · A2PLRC

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Hansoh Pharmaceutical Group Company 마진 역사

Hansoh Pharmaceutical Group Company 주식 매출, EBIT, 주당 순이익 KYG549581067 · A2PLRC

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Hansoh Pharmaceutical Group Company 매출, 이익 및 EBIT 주당 역사

Hansoh Pharmaceutical Group Company 주식 및 주식 분석

Hansoh Pharmaceutical Group Company 역사적인 P/E, EBIT 및 P/S에 따른 평가

Hansoh Pharmaceutical Group Company 주식 수량 KYG549581067 · A2PLRC

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Hansoh Pharmaceutical Group Company 주식 배당금 KYG549581067 · A2PLRC

배당금

배당금에 대한 개요

해석 및 사용

투자 전략

Hansoh Pharmaceutical Group Company 배당금 내역

Hansoh Pharmaceutical Group Company 주식 배당률 KYG549581067 · A2PLRC

배당비율

연간 배당비율이란 무엇인가요?

데이터 해석 방법

투자에 대한 데이터 사용

Hansoh Pharmaceutical Group Company 배당금지급률 역사

Hansoh Pharmaceutical Group Company 수익 예상

Hansoh Pharmaceutical Group Company 수익 놀라움

Eulerpool ESG Scorecard© Hansoh Pharmaceutical Group Company 주식을 위해

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

Hansoh Pharmaceutical Group Company 주식 주주 구조

Hansoh Pharmaceutical Group Company 임원진 및 경영진

Hansoh Pharmaceutical Group Company 주식에 대한 자주 묻는 질문

What values and corporate philosophy does Hansoh Pharmaceutical Group Company represent?

In which countries and regions is Hansoh Pharmaceutical Group Company primarily present?

티커
3692.HK

ISIN
KYG549581067

WKN
A2PLRC